产品
  • 产品
  • 供应商
  • 采购
  • 资讯
  • 会展
猜你想搜
首页 制药产品大全 生物制品 生化原料药 Pasireotide

Pasireotide

2026-10-31

产品详情

Pasireotide
肽类
396091-73-9
中国药典,美国药典,欧洲药典
药用级
Signifor/=orphan drug/=treatment of Cushing's disease
否
As per requirement
As per requirement
10克
capacity >10,000 grams
2周-4周
中国,北美洲,东欧,亚洲,中东
无

产品描述

Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

The most common side effects include hyperglycaemia (high blood sugar levels), diabetes, diarrhoea, abdominal pain (stomach ache), nausea (feeling sick), cholelithiasis (gallstones), injection site reactions, and tiredness.

Pasireotide was approved for Cushing's disease by the European Medicines Agency (EMA) in April 2012 and by the U.S. Food and Drug Administration (FDA) in December 2012.

Pasireotide LAR (the long-acting-release formulation) was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMA in September 2014.

苏州法默赛科技有限公司
访问店铺
注册资本
公司地址
联系人

公司简介

以“关爱生命、健康至上、可负担的API”为使命,我们希望与您携手合作,实现共赢,共同促进健康生活。 我司主要产品包括 司美格鲁肽、替尔泊肽、利拉鲁肽、依替巴肽、加尼瑞克、醋酸格拉替雷、特利加压素乙酸盐、奥曲肽乙酸盐、催产素乙酸盐、去氨加压素、亮丙瑞林、醋酸西曲瑞克、醋酸卡贝缩宫素、醋酸阿托西班、利那洛肽。
业务类型:
成立日期:
年营业额:
主营产品类别: